PSA response to cabazitaxel is associated with improved progression-free survival in metastatic castration-resistant prostate cancer: the non-interventional QoLiTime study
To evaluate the association between prostate-specific antigen (PSA) response and progression-free and overall survival in men with metastatic castration-resistant prostate cancer (mCRPC) treated with cabazitaxel.
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
5 January 2018
|
| In: |
World journal of urology
Year: 2018, Volume: 36, Issue: 3, Pages: 375-381 |
| ISSN: | 1433-8726 |
| DOI: | 10.1007/s00345-017-2138-x |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1007/s00345-017-2138-x
|
| Author Notes: | Peter Hammerer, Salah-Eddin Al-Batran, Christine Windemuth-Kieselbach, Martin Keller, Ralf-Dieter Hofheinz |
| Summary: | To evaluate the association between prostate-specific antigen (PSA) response and progression-free and overall survival in men with metastatic castration-resistant prostate cancer (mCRPC) treated with cabazitaxel. |
|---|---|
| Item Description: | Gesehen am 16.06.2020 |
| Physical Description: | Online Resource |
| ISSN: | 1433-8726 |
| DOI: | 10.1007/s00345-017-2138-x |